Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.
The PLAJEX™ 0.5mL Luer Lock Silicone oil-free pre-fillable syringe is specifically designed for challenging low dose Pre-Filled Syringe (PFS) products, making it suitable for high-value drug applications such as intravitreal injection, thus enabling our customers to offer a safe, easy-to-use, and effective treatment option for patients with ophthalmic disorders.
As the latest addition to the PLAJEX™ Ready-to-Fill Polymer Syringe range, these primary container solutions come sterilized, ready for filling, offering silicone oil-free containers made of Cyclo Olefin Polymer (COP) with tight dimensional tolerances, as well as a clear dose mark for dose confirmation, enabling our customers to overcome ophthalmic delivery and commercialization challenges.
Terumo's proprietary i-coating™ stopper technology eliminates the need of silicone oil in the syringe system while providing consistent and predictable break-loose and glide forces. It will prevent silicone oil being injected into patients, which is known to cause silicone oil droplet formation in their eyes. In addition, eliminating the use of silicone oil in the PFS system significantly reduces the sub-visible particle load, and we enable our customers to fulfil stringent particle requirements such as USP <789> Particulate Matter in Ophthalmic Solutions.
Enhanced user experience is key. The syringe system is provided with a finger grip with ergonomic design and backstop function, an easy grip twist-off tip cap, and integrated luer lock for secure needle connection.
Philippe Lauwers, Technology Development Director, said: "This is an innovative container closure system that combines the unique values of a polymer primary container with the silicone oil-free rubber stopper technology to provide safe and more convenient treatments for patients. Our latest product demonstrates the company's commitment to provide innovative technologies that support our customers and put patients in the centre of everything we do."
Yuki Takeuchi, Global Product Manager, PLAJEX™, added: "Intravitreal injections are becoming an important addition to treatment options for improved eyesight or vision, and we have seen demand rising steadily over the past decade. There are several challenges involved in the design of a prefilled syringe for safe administration of ophthalmic drugs and other sensitive low-dose drugs. Therefore, we are happy to provide a solution to solve these challenges and improve the quality of life for patients."
PLAJEX™ 0.5mL Luer Lock Silicone oil-free pre-fillable syringe
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, and primary packaging solutions. Terumo Pharmaceutical Solutions has decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to the latest stages of product commercialization to optimize critical aspects of parenteral drug delivery. Our comprehensive parenteral delivery product portfolio of injection, infusion, and primary packaging solutions offers innovative drug delivery technologies ready for today's most demanding applications.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.